Methods for determining resistance to neuraminidase inhibitors

International Congress Series

Volumn 1219, Issue C, 2001, Pages 879-886

  Tisdale, Margaret ^a   Daly, Janet ^a   Gor, Dee ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Neuraminidase inhibitors; Susceptibility monitoring

Indexed keywords

EID: 0344595918     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00656-2     Document Type: Article

References (27)

1. Belshe, R.B., Smith, M.H., Hall, C.B., Betts, R., Hay, A.J., Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62 (1988), 1508–1512.
2. Gubareva, L.V., Mastrosovich, M.N., Brenner, M.K., Bethell, R.C., Webster, R.G., Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998), 1257–1262.
3. Kellam, P., Larder, B.A., Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38 (1994), 23–30.
4. von Itzstein, M., Wu, W.Y., Kok, G.B., Dyason, J.C., Jin, B., Phan, T.V., Smythe, M.L., White, H.F., Oliver, S.W., Colman, P.M., Varghese, J.N., Ryan, D.M., Woods, J.M., Bethell, R.C., Hotham, V.J., Cameron, J.M., Penn, C.R., Rational design of potent sialidase based inhibitors of influenza virus replication. Nature 363 (1993), 418–423.
5. Kim, C.U., Lew, W., Williams, M.A., et al. Influenza NA inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119 (1997), 681–690.
6. Sudhaker Babu, Y., Pooran, C., Bantia, S., Kotian, P., Dehghani, A., El-Kattan, Y., Lin, T.-H., Hutchinson, L., Elliott, A.J., Parker, C.D., Ananth, S.L., Horn, L.L., Laver, G., Montgomery, J.A., BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure based drug design. J. Med. Chem. 43 (2000), 3482–3486.
7. Barnett, J.M., Cadman, A., Gor, D., Dempsey, M., Walters, M., Candlin, A., Tisdale, M., Morley, P.J., Owens, I.J., Fenton, R.J., Lewis, A.P., Claas, E.C.J., Rimmelzwaan, G.F., DeGroot, R., Osterhaus, A.D.M.E., Zanamivir susceptibility monitoring and characterisation of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:1 (2000), 78–87.
8. Gor, D., Cadman, A., Dempsey, M., Walters, M., Candlin, A., Barnett, J., Tisdale, M., Antiviral efficacy and sequence analysis of HA and NA genes of influenza isolates from zanamivir phase II/III clinical efficacy trials., 39th ICAAC (San Francisco, September, 1999) Abstract 284, 1999.
9. Covington, E., Mendel, D.B., Escarpe, P., Tai, C.Y., Soderbarg, K., Roberts, N.A., Phenotypic and genotypic assay of influenza neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir., Second International Symposium on Influenza and other Respiratory Viruses, Grand Cayman, Cayman Islands, December 10–12, 1999.
10. Blick, T.J., Tiong, T., Sahasrabudhe, A., Varghese, J.N., Colman, P.M., Hart, G.J., Bethell, R.C., McKimm-Breschkin, J.L., Generation and characterisation of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214 (1995), 475–484.
11. Staschke, K.A., Colacino, J.M., Baxter, A.J., Air, G.M., Bansal, A., Hornback, W.J., Munroe, J.E., Laver, G., Molecular basis for the resistanec of influenza viruses to 4-Guanidino-Neu5Ac2en. Virology 214 (1995), 642–646.
12. McKimm-Breschkin, J.L., Blick, T.J., Sahasrabudhe, A., Tiong, T., Marshall, D., Hart, G.J., Bethell, R.C., Penn, C.R., Generation and characterization of variants of NWS/G7OC influenza virus after in vitro passage of 4-amino-Neu5Ac2en and 4-Guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40 (1996), 40–46.
13. McKimm-Breschkin, J.L., McDonald, M., Blick, T.J., Colman, P.M., Mutation in the influenza virus neuraminidase gene resulting in decreased susceptibility to the neuramindiase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225 (1996), 240–242.
14. Penn, C.R., Barnett, J.M., Bethell, R.C., et al. Selection of influenza virus with reduced sensitivity in vitro to the NA inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in the HA may compensate for loss of NA activity. Brown, L.E., Hampson, W.A., Webster, R.G., (eds.) Options for the Control of Influenza, 1996, Elsevier, Amsterdam, Netherlands.
15. Gubareva, L.V., Bethell, R., Hart, G.J., Murti, K.G., Penn, C.R., Webster, R.G., Characterisation of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70 (1996), 1818–1827.
16. Gubareva, L.V., Robinson, M.J., Bethell, R., Webster, R.G., Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71 (1997), 3385–3390.
17. Blick, T.J., Sahasrabudhe, A., McDonald, M., Owens, I.J., Morley, P.J., Fenton, R.J., McKimm-Breschkin, J.L., The interaction of neuraminidase and haemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246 (1998), 95–103.
18. Tai, C.Y., Escarpe, P.A., Sidwell, R.W., et al. Characterization of human influenza virus variants selected in vitro in the presence of the NA inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998), 3234–3241.
19. Barnett, J.M., Cadman, A., Burrell, F.M., Madar, S.H., Lewis, A.P., Tisdale, M., Bethell, R., In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265 (1999), 286–295.
20. Wang, Z.M., Tai, C.Y., Mendel, D.B., Characterization of an influenza virus variant selected in vitro in the presence of the neuraminidase inhibitor GS4071. The 13th International Congress on Antiviral Resesarch, Baltimore, MD, USA. April 16th–21st 2000 Antiviral Research, vol. 46, 2000, A60.
21. Carr, J., Ives, J., Roberts, N.A., Tai, C.Y., Mendel, D.B., Kelly, L., Lambkin, R., Oxford, J., An oseltamivir treatment-selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidasegene has reduced infectivity in vivo., Second International Symposium on Influenza and Other Respiratory Viruses, Grand Cayman, Cayman Islands, December 10–12, 1999.
22. Gubareva, L., Tai, C.Y., Mendel, D.B., Ives, J., Roberts, N.A., Hayden, F.G., Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1)virus infections in humans: selection of a novel neuraminidase variant. The 13th International Congress on Antiviral Research, Baltimore MD, USA, April 16th–21st 2000 Antiviral Research, vol. 46, 2000, A59.
23. Tisdale, M., Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10 (2000), 45–55.
24. Potier, M., Mameli, L., Belisle, L., Dallaire, L., Melancon, S.B., Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979), 287–296.
25. Buxton, R.C., Edwards, B., Juo, R.R., Voyta, J.C., Tisdale, M., Bethell, R.C., Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280 (2000), 291–300.
26. Hayden, F.G., Belshe, R.B., Clover, R.D., Hay, A.J., Oakes, M.G., Soo, W., Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321 (1989), 1696–1702.
27. Smee, D.F., Sidwell, R.W., Morrison, A.C., Bailey, K.W., Ly, L., Baum, E.Z., Wagaman, P.C., Bantia, S., Influenza A viruses resistant to the neuraminidase inhibitor RWJ-270201. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1158, 2000, 271.